Prognostic genome and transcriptome signatures in colorectal cancers

Luís Nunes(Uppsala University), Fuqiang Li(BGI Group (China)), Meizhen Wu(BGI Group (China)), Tian Luo(BGI Group (China)), Klara Hammarström(Uppsala University), Emma Torell(Uppsala University), Ingrid Ljuslinder(Umeå University), Artur Mezheyeuski(Uppsala University), Per‐Henrik Edqvist(Uppsala University), Anna Löfgren Burström(Umeå University), Carl Zingmark(Umeå University), Sofia Edin(Umeå University), Chatarina Larsson(Uppsala University), Lucy Mathot(Uppsala University), Erik Osterman(Uppsala University), Emerik Österlund(Uppsala University), Viktor Ljungström(Uppsala University), Inês Neves(Uppsala University), Nicole Yacoub(Uppsala University), Unnur Guðnadóttir(Uppsala University), Helgi Birgisson(Uppsala University Hospital), Malin Enblad(Uppsala University Hospital), Fredrik Pontén(Uppsala University), Richard Palmqvist(Umeå University), Xun Xu(Chinese Academy of Sciences), Mathias Uhlén(Science for Life Laboratory), Kui Wu(BGI Group (China)), Bengt Glimelius(Uppsala University), Cong Lin(BGI Group (China)), Tobias Sjöblom(Uppsala University)
Nature
August 7, 2024
Cited by 133Open Access
Full Text

Abstract

. Here, to understand the functional and prognostic impact of cancer-causing somatic mutations, we analysed the whole genomes and transcriptomes of 1,063 primary colorectal cancers in a population-based cohort with long-term follow-up. From the 96 mutated driver genes, 9 were not previously implicated in colorectal cancer and 24 had not been linked to any cancer. Two distinct patterns of pathway co-mutations were observed, timing analyses identified nine early and three late driver gene mutations, and several signatures of colorectal-cancer-specific mutational processes were identified. Mutations in WNT, EGFR and TGFβ pathway genes, the mitochondrial CYB gene and 3 regulatory elements along with 21 copy-number variations and the COSMIC SBS44 signature correlated with survival. Gene expression classification yielded five prognostic subtypes with distinct molecular features, in part explained by underlying genomic alterations. Microsatellite-instable tumours divided into two classes with different levels of hypoxia and infiltration of immune and stromal cells. To our knowledge, this study constitutes the largest integrated genome and transcriptome analysis of colorectal cancer, and interlinks mutations, gene expression and patient outcomes. The identification of prognostic mutations and expression subtypes can guide future efforts to individualize colorectal cancer therapy.


Related Papers